LANCE Ultra Total eIF2α kits are designed for the detection of total eIF2α (phosphorylated and non-phosphorylated) in cell lysates using a simple, homogeneous LANCE Ultra assay (no wash steps). This assay can be used as a normalization assay for phospho-eIF2α detection, and is compatible with both adherent and suspension cells.
true falseFor research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please note control lysates are sold separately, catalog number TRF4008S.
Formats:
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are homogeneous (no wash) TR-FRET (time-resolved fluorescence resonance energy transfer) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second antibody is labeled with an acceptor fluorophore [ULight™ dye]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm. Data are represented as ratiometric (665/615 nm X 10,000).
Eukaryotic initiation factor 2 (eIF2) is a heterotrimer which is involved in the initiation of translation in eukaryotes. EIF2 binds to two other partners, GTP and Met-tRNAi, and forms the 43S pre-initiation complex upon binding the 40S subunit. Under conditions of cellular stress, the alpha subunit can be phosphorylated at S51 to downregulate protein translation.
| Assay Target Class | Protein |
|---|---|
| Automation Compatible | Yes |
| Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
| Product Brand Name | LANCE Ultra |
| Shipping Condition | Blue Ice |
| Unit Size | 500 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
